Healthy Adults With Mild Cognitive Impairment (MCI) and a 16-week Intervention With Mitocholine™, a Functional Food Ingredient

Mild Cognitive Impairment Clinical Trial

Official title:

A Randomised, Double-blind, Placebo-controlled, Parallel-group Study in Otherwise Healthy Adults With Mild Cognitive Impairment (MCI) Assessing a 16-week Intervention With Mitocholine™, a Functional Food Ingredient

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05690724
• Other study ID #: AFCRO-155
• Status: Recruiting
• Phase: N/A
• Start date: January 9, 2023
• Est. completion date: September 18, 2024

Study information

• Verified date: November 2023
• Source: Mitocholine Ltd
• Contact: Eile Butler
• Phone: +353 21 430 7442
• Email: ebutler[@]atlantiatrials.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

To evaluate the effect of 16-weeks consumption of Mitocholine on Executive Function and Homocysteine levels in a population experiencing Mild Cognitive Impairment. The study will also include measures of memory, language, S-adenosylmethionone (SAM), Betaine, Choline.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 100
• Est. completion date: September 18, 2024
• Est. primary completion date: June 15, 2024
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 55 Years to 79 Years

Eligibility

Inclusion Criteria:

1. Willing to participate in the study and comply with its procedures.

2. Able to give written informed consent.

3. Adults aged 55 to 79 years, inclusive.

4. Meet MCI criteria, based on the Peterson criteria (Peterson et al., 1999):

1. Objective evidence of cognitive impairment as assessed by MoCA (score =18 to =25).

2. Absence of major depression as assessed by PHQ (score <10).

3. Activities of daily living score

• males =4

• females =7

5. Have a homocysteine level =11.0µmol/L (Smith D et al, 2018).

Exclusion Criteria:

1. Diagnosis of a major cognitive disorder (e.g. Alzheimer's or Parkinson's disease diagnoses; additionally, confirmation of a mini stroke (TIA) within the last 3 months would be an exclusionary condition).

2. Participants who are pregnant or wish to become pregnant during the trial.

3. Participants who are lactating and/or currently breastfeeding.

4. Participants currently of childbearing potential, but not using an effective method of contraception, as determined by the investigator.

5. Participants with active or a history of alcohol or substance abuse; (exclude elevated Gamma GT & clinically abnormal liver function test).

6. Uncontrolled diabetes (or glycated haemoglobin >7% / 53 mmol/mol).

7. Clinically significant heart, liver, or renal disease (at the discretion of the investigator).

8. Have uncontrolled hypertension SBP > 160mmHg, DBP > 100mmHg).

9. Participants prescribed medications likely to influence memory or mood, as determined by the investigator.

10. Participants with a history of depression (within past 24 months) or any concurrent medical, cognitive or psychiatric condition that would either: compromise his/her ability to comply with the study requirements, may pose significant risk to the participant, or be deemed exclusionary by the investigator

11. Have had any other condition or are taking a medication that the investigator believes would interfere with the objectives of the study, pose a safety risk, or confound the interpretation of the study results.

12. Change in supplements, medication, or major diet in 30 days prior to enrolment and throughout the study.

13. Taking any supplements or vitamins notably known to affect cognitive function (e.g. Living Nutrition Cognitive, Viridian Cognitive Complex, ginkgo biloba, fish oil etc., list not exhaustive), or any psychotropic medications and products which interact with acetylcholine esterase and/or NMDA receptors (6-week washout before screening). Vitamin D and Calcium supplements permitted if on a stable dose for the previous 3 months.

14. Users of inhaled nicotine products such as cigarettes or vape products with an inconsistent recent history of consumption i.e., those who have taken up smoking/vaping in the 12 months prior to screening, or those who have either given up or re-started smoking or vaping in the 12 months prior to screening, or those who intend to significantly modify their use of inhaled nicotine products during their participation in the study.

15. Has received treatment involving experimental drugs in the past 3 months.

16. Have a malignant disease or any concomitant end-stage organ disease, which, in the Investigator's judgment, contraindicates participation in the study.

17. Individuals who, in the opinion of the investigator, are considered to be poor clinical attendees or unlikely for any reason to be able to comply with the trial.

18. Any Participant who is an employee of the study site or an Atlantia Clinical Trials employee or their close family member or a member of their household.

Related Conditions & MeSH terms

• Cognitive Dysfunction
• Mild Cognitive Impairment

Intervention

Dietary Supplement:
• Mitocholine™ or Placebo
Participants will be instructed to consume one bottle of study product daily for the duration of the trial (16 weeks). They will be instructed to consume the product in the morning with breakfast.

Locations

Country	Name	City	State
Ireland	Atlantia Clinical Trials	Cork	Munster

Sponsors (2)

Lead Sponsor	Collaborator
Mitocholine Ltd	Atlantia Food Clinical Trials

Country where clinical trial is conducted

Ireland, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Absolute change in Executive Function Score in the Mitocholine group compared to the Placebo group.	Assessed by the verbal fluency, colour-word interference and trail making tests in the Delis-Kaplan Executive Function System	Baseline to end of intervention (week 16)
Primary	Absolute change in Homocysteine levels in the Mitocholine group compared to the Placebo group.	Assessed by serum Homocysteine levels (umol/L)	Baseline to end of intervention (week 16)
Secondary	Change in Choline levels in the Mitocholine group compared to the Placebo group	Assessed by Choline in blood	Baseline to end of intervention (week 16)
Secondary	Change in S-adenosylmethionone (SAM) levels in the Mitocholine group compared to the Placebo group	Assessed by S-adenosylmethionone (SAM) in blood	Baseline to end of intervention (week 16)
Secondary	Change in Betaine levels in the Mitocholine group compared to the Placebo group	Assessed by Betine in blood	Baseline to end of intervention (week 16)
Secondary	Change in Memory outcomes (visual memory) in the Mitocholine group compared to the Placebo group	Assessed by a Paired Associated Learning Task	Baseline to end of intervention (week 16)
Secondary	Change in Memory outcomes (episodic memory) in the Mitocholine group compared to the Placebo group	Assessed by a Word Recall Task	Baseline to end of intervention (week 16)
Secondary	Change in Language outcomes in the Mitocholine group compared to the Placebo group	Assessed by the Boston Naming Test	Baseline to end of intervention (week 16)